Members of the CLS’ Board of Directors and management have entered into declarations of intent to subscribe for new B-shares in connection with the exercise of warrants of series TO 5 B
Lund, Sweden – Members of the Board of Directors and management of Clinical Laserthermia Systems AB's ("CLS" or "Company") have entered into declarations of intent to exercise all of their warrants of series TO 5 B to subscribe for new B-shares in the Company's upcoming warrant exercise, corresponding a total of approximately SEK 200,000.
Each warrant of series TO 5 B entitles the holder to subscribe for one (1) new B-share in CLS to the subscription price that has been set at SEK 0.46 per share.
Members of the Board of Directors and management of the Company have entered into declarations of intent to exercise all of their warrants of series TO 5 B to subscribe for new B-shares in CLS. The declarations of intent correspond to a total of approximately SEK 200,000.
For more information about the warrants of series TO 5 B, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information about CLS, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
www.clinicallaser.se
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The productsare marketed for image-guided laser ablation and used in studies for treatment with imILT®, The Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: www.clinicallaser.se